EMA: Granting of a marketing authorisation for the medicinal product Siltuximab [Sylvant] for the treatment of multicentric Castleman’s Disease (MCD) recommended.

On 20 March 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sylvant, 100 mg and 400 mg, Powder for concentrate for solution for infusion intended for the treatment of multicentric Castleman’s disease (MCD). Sylvant was designated as an orphan medicinal product on 30 November 2007. The applicant for this medicinal product is Janssen-Cilag International NV. They may request a re-examination of any CHMP opinion, provided they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The active substance of Sylvant is siltuximab, a human‑mouse chimeric monoclonal antibody that specifically binds to and neutralizes human IL-6 with high affinity. The benefits with Sylvant are its ability to reduce the tumour burden and to improve the symptoms in MCD patients. The most common side effects are infections (including upper respiratory tract infections), pruritus, and maculopapular rash. A pharmacovigilance plan for Sylvant will be implemented as part of the marketing authorisation.

The approved indication is: “Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus‑8 (HHV‑8) negative”. It is proposed that Sylvant should be administered by qualified healthcare professionals and under appropriate medical supervision.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for Sylvant and therefore recommends the granting of the marketing authorisation.

Tags: , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • How hormone therapy slows progression of atherosclerosis September 28, 2020
    As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis. A study based on Early Versus Late Intervention Trial With Estradiol (ELITE) data evaluated the underlying mechanism of such benefit and will be presented during the […]
  • Newer Type 2 diabetes medications have heart and kidney disease benefits, too September 28, 2020
    Two newer classes of medications used to treat Type 2 diabetes have been shown to protect patients against heart disease and chronic kidney disease, in addition to their ability to help manage blood glucose. Patients with Type 2 diabetes have a high rate of chronic kidney and cardiovascular disease and more serious complications; these newer […]
  • Cannabis use for menopause symptom management September 28, 2020
    CLEVELAND, Ohio (September 28, 2020)--As legislation relaxes regarding cannabis, it is being used to manage numerous chronic health conditions and mood symptoms. A new study indicates that a growing number of women are either using cannabis or want to use it for the management of bothersome menopause symptoms. Study results will be presented during the […]
  • Advances in nonhormone therapies provide women with more options for managing hot flashes September 28, 2020
    Although many women manage menopause symptoms with hormone therapy, increasing numbers of women are considering nonhormone options. Dr. Susan Reed from the University of Washington School of Medicine is a featured speaker during the 2020 Pre-Meeting Symposium of The North American Menopause Society (NAMS) and will discuss the latest advances in nonhormone hot flash management. […]
  • 1 in 3 parents plan to skip flu shots for their kids during COVID-19 pandemic September 28, 2020
    The pandemic doesn't seem to be changing parents' minds about the importance of the flu vaccine.
Top